Compare SAR & LCTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SAR | LCTX |
|---|---|---|
| Founded | 2007 | 1990 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 233.9M | 251.4M |
| IPO Year | 2006 | 1996 |
| Metric | SAR | LCTX |
|---|---|---|
| Price | $15.14 | $0.95 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 7 | 7 |
| Target Price | ★ $20.00 | $5.50 |
| AVG Volume (30 Days) | 164.2K | ★ 1.5M |
| Earning Date | 10-06-2026 | 11-05-2026 |
| Dividend Yield | ★ 19.58% | N/A |
| EPS Growth | ★ 14.36 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $14,556,000.00 |
| Revenue This Year | $0.78 | $4.38 |
| Revenue Next Year | $6.28 | $10.80 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 53.24 |
| 52 Week Low | $13.78 | $0.88 |
| 52 Week High | $24.07 | $2.09 |
| Indicator | SAR | LCTX |
|---|---|---|
| Relative Strength Index (RSI) | 29.38 | 46.61 |
| Support Level | $13.78 | $0.88 |
| Resistance Level | $23.85 | $1.18 |
| Average True Range (ATR) | 0.53 | 0.06 |
| MACD | -0.02 | 0.01 |
| Stochastic Oscillator | 38.03 | 45.61 |
Saratoga Investment Corp is a specialty finance company that provides customized financing solutions to U.S. middle-market businesses. The company invests in senior and unitranche leveraged loans and mezzanine debt, and, to a lesser extent, equity to provide financing for change of ownership transactions, strategic acquisitions, recapitalizations and growth initiatives in partnership with business owners, management teams and financial sponsors. Its objective is to create attractive risk-adjusted returns by generating current income and long-term capital appreciation from its debt and equity investments.
Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline currently includes: OpRegen, OPC1, ReSonance, ILT1, RND1, PNC1, and LCT-CON. Its programs are based on its proprietary, in-house, cell-based manufacturing platform, which it call AlloSCOPE (Allogeneic, Scalable, Consistent, Off-the-shelf, Pluripotent Cell Engineering), and supported by its associated development, formulation, manufacturing, and delivery capabilities. The AlloSCOPE platform is a proprietary differentiation and production modality from which, a single, well-characterized pluripotent cell line can create a stable current Good Manufacturing Practice, master cell bank.